#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial hypertriglyceridaemia Retinopathy of prematurity Pulmonary tuberculosis Antiphospholipid antibodies Ocular myasthenia Bone marrow disorder Inflammatory myofibroblastic tumour Albright's disease Krabbe's disease Neuropathy peripheral Vulval cancer Pustular psoriasis VEXAS syndrome PIK3CA-activated mutation Acute lymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Cytokine release syndrome – Diagnostics Pleural mesothelioma malignant – Diagnostics Fabry’s disease – Basic Information Rosai-Dorfman syndrome – Basic Information Alagille syndrome Krabbe’s disease – Life with Disease Waldenstrom’s macroglobulinaemia – Trials in Disease Adrenogenital syndrome – Treatment Breast angiosarcoma – Diagnostics Progressive supranuclear palsy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tyra-300-B01 Doxycycline Hyclate GVV858 SRSD107 Doconexent Fulvestrant Apremilast Dantrolene Sodium Sotalol Olmesartan Medoxomil Cetrelimab Ima402 Umeclidinium Bromide Dermatophagoides Pteronyssinus Povetacicept Brentuximab Vedotin Tamsulosin Hydrochloride Golimumab Azd3470 CARBACHOL More therapies…

    Learn about Your Condition

    Oesophageal achalasia Oesophageal disorder Catatonia Colonoscopy Leiomyosarcoma metastatic Retinal vein occlusion Laparotomy Endometrial cancer Deafness Sarcoma metastatic Hepato-lenticular degeneration Acute respiratory failure Gestational diabetes Drug use disorder Anal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Simplex Kft.

Simplex Kft.

Facan Utca 2, Sostohegy, Nyiregyhaza, 4481, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Beclometasone Dipropionate
    • Beclometasone Dipropionate Anhydrous
    • Formoterol Fumarate Dihydrate
    Bulgaria Czechia Germany Hungary Latvia Poland +2

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tezepelumab
    Belgium Bulgaria Denmark France Greece Hungary +3

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Formoterol Fumarate Dihydrate
    • Budesonide
    • Glycopyrronium Bromide
    Austria Bulgaria Czechia Denmark Finland France +10

  • A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tozorakimab
    • Salbutamol
    Belgium Bulgaria Czechia Denmark Finland France +11

  • Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Salbutamol Sulfate
    • Tozorakimab
    Belgium Bulgaria Czechia Denmark Finland Hungary +5

  • Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

    Not recruiting

    3 1
    Investigated Diseases:
    • Hypercholesterolaemia
    Bulgaria Czechia Germany Hungary Poland Slovakia +1

  • Study on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Beclometasone Dipropionate Anhydrous
    • Formoterol Fumarate Dihydrate
    • Glycopyrronium Bromide
    Bulgaria Czechia Hungary Poland Romania

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!